pegfilgrastim

Home
Ligands
pegfilgrastim

GtoPdb Ligand ID: 6969

Synonyms: Neulasta®

pegfilgrastim is an approved drug (FDA and EMA (2002))

Compound class: Peptide or derivative

Comment: This is a PEGylated version of recombinant human G-CSF. Pegylation increases circulating half-life. In addition to pegfilgrastim, lipegfilgrastim (Lonquex®) is a glyco-PEGylated long-acting G-CSF, that is an alternative to pegfilgrastim [1].

Biosimilars:

Name	Trade name	Company	Clinical phase	Indications
pegfilgrastim-jmbd; MYL-1401H	Fulphila	Mylan	Approved (2018 FDA & EMA)	As per reference agent [2]
	Pelgraz	Accord	Approved (2018 EMA)	As per reference agent
	Pelmeg	Mundipharma (developed by Cinfa Biotech)	Approved (2018 EMA)	As per reference agent
	pegfilgrastim Mundipharma	Mundipharma	Approved (2019 EMA)	As per reference agent
pegfilgrastim-cbqv; CHS-1701	Udenyca	ERA Consulting; Coherus BioSciences	Approved (2018 FDA & EMA)	As per reference agent
USV pegfilgrastim	Grasustek	Juta Pharma	Approved (2019 EMA)	As per reference agent
pegfilgrastim-bmez; LA-EP2006	Ziextenzo	Sandoz	Approved (2018 EMA, 2019 FDA)	As per reference agent
pegfilgrastim-apgf; PF-06881894	Nyvepria	Pfizer	Approved (2020 FDA)	As per reference agent
pegfilgrastim-fpgk; MSB11455	Stimufend	Fresenius Kabi	Approved (2022 FDA & EMA)	As per reference agent
pegfilgrastim-pbbk	Fylnetra	Amneal Pharmaceuticals	Approved (2022 FDA)	As per reference agent